Why is Pharming stock climbing today?

Pharming stock rose 3.0% to trade at €1.086 as the Leiden-based biotechnology company published its complete third-quarter 2026 financial results, confirming revenue growth of 21% to $117.6 million against a prior analyst consensus of roughly $103.5 million, and an 89% jump in operating profit to $29.9 million from $15.8 million in the same period a year earlier. Net profit came in at $22.4 million, nearly tripling from $7.5 million in Q3 2025, supported by higher revenues and government grants for research and development.

Both of Pharming’s commercial products contributed to the beat. RUCONEST, the company’s flagship hereditary angioedema treatment, posted a 14% revenue increase to $93.8 million, reflecting demand stabilization and a seasonal inventory build, while Joenja (leniolisib) delivered a 58% revenue jump to $23.8 million on the back of strong U.S. patient growth, new international launches in Germany and Japan, and an expanded pediatric label in the United States.

Management also pointed to upcoming Phase II data for leniolisib in common variable immunodeficiency patients, expected in November, as a near-term pipeline catalyst. The company tightened its full-year 2026 revenue guidance to $380 million–$390 million, narrowing the prior range of $375 million–$395 million.

The broader market provided a largely neutral backdrop, with major global indices trading flat to marginally lower on the day, meaning Pharming’s move was driven almost entirely by company-specific factors rather than sector or macro tailwinds. The stock has been recovering from a difficult mid-year period that included a CEO departure and a guidance cut that sent shares toward their 52-week low of €0.82.

The combination of a decisive earnings beat, a tightened guidance range signaling management confidence, and a promising near-term pipeline event in November converged to push the shares higher today, extending a rebound that began when preliminary Q3 revenue figures were first disclosed on October 22.